Probiotics Reduce Inflammation in Depression, Meta-Analysis

Depression is not only a brain disorder. Evidence accumulated over the past decade shows it has a measurable inflammatory component, with elevated levels of circulating proteins like C-reactive protein (CRP) found consistently in people with major depression. If that inflammation plays a functional role in driving symptoms – and a growing body of research suggests it does – then the gut microbiome, which regulates much of the immune system, becomes a potentially important therapeutic target. A new meta-analysis published in Progress in Neuro-Psychopharmacology and Biological Psychiatry now adds quantified evidence: probiotics can significantly lower CRP and tumor necrosis factor-alpha (TNF-alpha) in patients already diagnosed with depression.

Key Takeaways

• Across 10 randomized controlled trials with 486 total participants, probiotic supplementation reduced serum CRP by an average of 0.74 mg/L (95% CI: -1.18 to -0.30) and significantly lowered TNF-alpha (WMD = -0.23; 95% CI: -0.43 to -0.04).
• A borderline reduction in interleukin-1 beta (IL-1beta) was also observed. No significant effects were found for IL-6 or IL-10, indicating a selective rather than broad-spectrum inflammatory response.
• The pooled sample of 486 participants is relatively small, and trials varied considerably in probiotic strain, dose, and duration, making it difficult to identify optimal protocols.
• The evidence points toward probiotics as a potential complement to existing treatment, not a replacement.

Probiotics Reduce CRP and TNF-alpha in Clinically Depressed Patients

The meta-analysis, conducted by Lachinani and Milajerdi, pooled data from 10 randomized controlled trials identified through a comprehensive search of PubMed, Google Scholar, Scopus, Embase, Web of Science, and the Cochrane Library. All included studies tested probiotic supplementation in adult patients with a clinical diagnosis of depression and measured circulating inflammatory biomarkers.

Using random-effects models – the statistically appropriate approach when combining studies that vary in design – the authors computed pooled weighted mean differences (WMDs) with 95% confidence intervals. CRP dropped by a statistically significant 0.74 mg/L (95% CI: -1.18 to -0.30). TNF-alpha decreased significantly (WMD = -0.23; 95% CI: -0.43 to -0.04). A borderline reduction was observed for interleukin-1 beta (IL-1beta; WMD = -0.03; 95% CI: -0.07 to 0.00). No significant effects were found for IL-6 (WMD = -0.10; 95% CI: -0.22 to 0.03) or IL-10 (WMD = 0.08; 95% CI: -0.22 to 0.38).

Depression and Inflammation: Why Targeting the Gut Makes Sense

The gut-brain axis – the bidirectional communication pathway linking the gut microbiome to brain function and mood – offers a plausible mechanism for why probiotics might reduce inflammation in depressed patients. The gut microbiome plays a central role in calibrating the immune system. When microbial communities are disrupted, inflammatory signals can increase, and those signals appear to influence brain chemistry and mood regulation.

Probiotics that shift gut microbiome composition favorably could reduce inflammation through multiple routes – by producing short-chain fatty acids that modulate immune cell activity, or by reinforcing the gut epithelial barrier that prevents bacterial products from triggering systemic immune responses. The fact that CRP and TNF-alpha responded while IL-6 and IL-10 did not suggests the effect is more targeted in its immune pathway than a global anti-inflammatory response.

How a Meta-Analysis Strengthens Individual Trial Data

A systematic review and meta-analysis pools data across multiple trials rather than relying on any single study's results, and is considered among the higher-quality approaches available in clinical research. Ten trials is a modest foundation for a meta-analysis, but the comprehensive search strategy and use of random-effects models – which account for genuine differences between studies rather than assuming uniform effects – makes the statistical approach appropriate for the available evidence.

The authors searched databases through October 2025, ensuring the analysis captured recent trial data. The selection criteria were specific: adult patients with diagnosed depression, measuring actual circulating inflammatory biomarkers in randomized controlled trials.

What This Means for People with Depression

These findings are most directly relevant to the substantial proportion of people with depression who have an elevated inflammatory profile. Prior clinical research has demonstrated that specific probiotic add-on therapy in depressed patients can produce detectable changes in gut microbial composition, neural activity, and depressive symptom scores alongside inflammatory reductions – suggesting the biomarker changes seen in this meta-analysis may translate into functional outcomes.

What this does not establish is whether the reduction in CRP by 0.74 mg/L is large enough to produce meaningful symptom improvement in most patients, or which patients with depression benefit most. Probiotics should be considered a potential complement to evidence-based treatment for depression – not a replacement. Anyone managing depression with a care team should raise this evidence with their clinician rather than acting on it unilaterally.

The Key Limits of This Evidence

The pooled sample of 486 people across 10 trials is relatively small for a condition as common and heterogeneous as depression. More importantly, the trials used different probiotic formulations – different strains, doses, and treatment durations – which creates substantial heterogeneity that limits the ability to draw conclusions about what specifically drives the observed effects or what an optimal protocol looks like.

The absence of a significant effect on IL-6 is notable, given that IL-6 is one of the most commonly elevated inflammatory markers in depression. Whether this reflects a true null effect or insufficient statistical power from the small pooled sample is not resolvable from this analysis. Broader reviews of psychobiotic research have similarly concluded that the signal for mental health benefits from probiotics is present but confidence around optimal use remains wide.

What Larger Trials Need to Test

The authors call for larger, longer-term randomized controlled trials with standardized probiotic formulations to validate these findings and identify best protocols. Key open questions include: which strains specifically drive CRP and TNF-alpha reduction; whether inflammatory reduction correlates with symptom improvement; what duration of supplementation is required; and whether effects differ by depression subtype or baseline inflammatory status.

Common Questions

Can probiotics replace antidepressants? No. This study provides evidence that probiotics can reduce certain inflammatory markers in depressed patients, but does not show they treat depression independently. They may eventually function as a useful add-on to existing care, but that requires further confirmation in larger trials.

Which probiotic strains were used in these trials? The meta-analysis pooled trials using different formulations. The published abstract does not break down effects by strain, so this analysis cannot support a specific product recommendation.

What does a 0.74 mg/L reduction in CRP actually mean? CRP is a general marker of systemic inflammation. A reduction of 0.74 mg/L is a modest effect. Whether it translates to detectable symptom improvement has not been directly established in this analysis and remains an open question for future trials.

References

1. Faeze Lachinani, Alireza Milajerdi (2026). Effects of probiotic supplementation on inflammatory biomarkers in patients with depression: A systematic review and meta-analysis of randomized controlled trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2026.111944
2. Mustafa M. Shokr, Reem M. Eladawy, Yasmena O. Azar, Seham M. Al Raish (2025). Probiotics and the Gut–Brain Axis: Emerging Therapeutic Strategies for Epilepsy and Depression Comorbidity. Foods. https://doi.org/10.3390/foods14172926
3. Anna-Chiara Schaub, Else Schneider, Jorge F. Vazquez-Castellanos, et al. (2022). Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial. Translational Psychiatry. https://doi.org/10.1038/s41398-022-01977-z
4. Ling-Yi Dai, Ru-Ru Chen, Hao-Ran Chen, et al. (2025). Potential clinical benefits of probiotics, prebiotics, synbiotics, and postbiotics for depression via the microbiota-gut-brain axis. World Journal of Psychiatry. https://doi.org/10.5498/wjp.v15.i5.98436